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DEAR EDITOR, Epidermolytic ichthyosis (EI) is a rare genodermato-
sis caused by mutations in keratins 1 or 10. The available treat-
ment options for this debilitating condition, such as retinoids,
are highly unsatisfactory and associated with severe adverse
effects.1 A promising novel approach for the treatment of keratin
disorders may be to upregulate the expression of compensatory
keratins and/or to downregulate the expression of the mutated
keratins by neuroendocrine mediators that profoundly modulate
the expression of selected keratins.2 The current illustration
underscores the potential of this as yet untapped, innovative
treatment strategy for inherited human keratin disorders. Here
we show that the cannabinoid receptor 1 agonist, arachidonyl-
20-chloroethylamide (ACEA) (1 lmol L1, 48 h), can upregu-
late the expression of keratin 10 protein in human epidermis,
and decrease that of keratin 1 in human skin organ culture.
Although it remains to be examined how reproducible the speci-
fic keratin-regulatory effects shown here are in skin from differ-
ent patients, one wonders: can appropriate modulation of
cannabinoid signalling (e.g. by topically applied agents) suppress
mutated keratin 1 and upregulate the expression of functionally
compensatory keratin 10 in patients with EI?
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Join us for the 17th World Congress on Cancers of the
Skin in Sydney, from 15–18 August 2018!
Australia has one of the highest rates of skin cancer anywhere
in the world and is an ideal location to host the Skin Cancer
Foundation’s World Congress on Cancers of the Skin
(WCCS 2018). WCCS 2018 will be held in Sydney’s Interna-
tional Convention and Exhibition Centre from 15–18 August
2018.
Connect science with medical practice, and submit your
abstract before 3 November 2017. The Scientific Program will
feature invited speakers, Professor Richard Scolyer, Professor
Georgina Long and more to discuss key themes concerning
melanoma and non-melanoma skin cancers.
Registrations and accommodation bookings are open!
Secure your bookings early to avoid disappointment. For more
information including sponsorship opportunities, please visit
wccs2018.com.
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